Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Infographics

Seeing a return on investment in pharma marketing means understanding what happens to every dollar.

Engagement Manager, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Digital & Analytics, Oliver Wyman

Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting

Our new advice for the Blues, who are in a formative period as market trends create both sizable risk and sizable opportunity.

Principal, Oliver Wyman Actuarial Consulting
Global Head, Health Services, Oliver Wyman
Principal, Oliver Wyman

In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, Oliver Wyman
Engagement Manager, Health & Life Sciences, Oliver Wyman

2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

Some of our 2017 healthcare predictions on value-based care, consumers, mergers, startups, and pharma came true, while others were less predictable.

Principal, Oliver Wyman

As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Trendspotting in unpredictable times. This infographic highlights five predictions for 2017.

Managing Partner, Health & Life Sciences, Oliver Wyman
Head of Health & Life Sciences, North America, Oliver Wyman

Through this series of infographics, learn how payers, providers, and life sciences companies will be impacted by our 45th president.

Partner, Health & Life Sciences, Oliver Wyman

The Deal features David Campbell on how healthcare companies can leverage royalties, not their balance sheets, to fund innovation.

Partner, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe